For most of the last half-century, the story of appetite has been a story about neurons. Hunger neurons fire; fullness neurons fire back; hormones from the gut and fat tissue tip the balance. Drugs like semaglutide were built on that map.
Two studies published this spring suggest the map was missing several of its busiest intersections, and that one of them does not involve neurons at all.
The most direct example was published in the Proceedings of the National Academy of Sciences on April 6. Researchers found that the signal telling the brain a meal has arrived passes through two other cell types before a neuron ever hears about it.
A Chain of Three Cell Types, Only One of Them a Neuron
The work was led by scientists at the University of Concepción in Chile, with collaborators at the University of Maryland, and it starts with tanycytes, cells lining a fluid-filled cavity deep in the brain that monitor glucose as it moves through cerebrospinal fluid.
After a meal, glucose rises. Tanycytes process it and release lactate into the surrounding tissue. The assumption had been that lactate then spoke directly to appetite-control neurons. It does not, or at least not only.
Instead, the lactate binds to a receptor called HCAR1 on astrocytes, the support cells that outnumber neurons throughout the brain. Activated astrocytes release glutamate, which reaches POMC neurons, the population that suppresses appetite and generates the sensation of fullness.
"To put it simply, we found that tanycytes 'talk' to astrocytes, and then astrocytes 'talk' to neurons," Ricardo Araneda, a University of Maryland biology professor and corresponding author, said in the university's announcement.
In one experiment, delivering glucose to a single tanycyte triggered responses in multiple surrounding astrocytes, suggesting that a tiny, localized event ripples outward across a network. The team also observed evidence of a dual effect: the paper reports that lactate may simultaneously activate fullness neurons via astrocytes while quieting hunger neurons through a more direct route.
A Hormone That Signaled to the Wrong Brain Region
A second surprise came from a team at the University of Oklahoma and the University of Iowa. FGF21 is a naturally occurring hormone that reverses obesity in mice and is already under investigation for metabolic liver disease. Researchers knew it acted on the brain rather than the liver, work the same group detailed in Endocrinology. They did not know where.
The obvious candidate was the hypothalamus, the region most associated with body weight. Writing in Cell Reports, the team showed the signal instead goes to the hindbrain, specifically beta-klotho-expressing neurons in the nucleus of the solitary tract and the area postrema, which project to the parabrachial nucleus. Those neurons proved both necessary and sufficient for FGF21's effects on energy expenditure and weight loss.
"We thought we would find that it signalled to the hypothalamus, which is widely implicated in body weight regulation, so we were very surprised to discover that the signal was to the hindbrain, which is where the GLP-1 analogs are believed to act," senior author Matthew Potthoff told Drug Target Review.
Same neighborhood, different mechanism. GLP-1 medications reduce food intake largely by suppressing appetite. FGF21 appears to raise metabolic rate, causing animals to burn more energy rather than making them want less food.
What None of This Means Yet
All of it is animal work, and the limitations are specific rather than generic.
The astrocyte pathway has been mapped in animal models, though both cell types are present in humans. Araneda's team has not yet shown that manipulating HCAR1 changes eating behavior, which is the experiment that would matter. The FGF21 study used only male mice, because females do not gain as much weight on a high-fat diet, so no sex-stratified analysis was possible. The authors also note that they did not fully establish the downstream tissues through which hindbrain signaling produces its metabolic effect.
No approved drug targets either pathway. Both teams describe their findings as potential complements to existing therapies rather than replacements. Araneda framed HCAR1 as "a novel target that may complement existing therapies like Ozempic, for example." Potthoff's stated hope is that identifying the precise circuit yields drugs that work without the side effects that drive patients off current medications.
What the research does establish is a framing point worth stating plainly: body weight is defended by a distributed system with redundant components, which is one reason it resists deliberate change and reasserts itself when medication stops. That is a description of physiology, not a prescription. Anyone weighing treatment options should work through them with a qualified clinician.
Key Questions Answered
What is the newest finding?
Research in PNAS shows that after a meal, tanycytes release lactate that activates astrocytes via the HCAR1 receptor, and these astrocytes then signal the POMC neurons responsible for satiety.
Why does it matter that astrocytes are involved?
Astrocytes were long treated as passive support cells. Finding them in the middle of the satiety pathway opens a target class that current appetite drugs do not address.
How is FGF21 different from Ozempic?
Both act on hindbrain regions, but GLP-1 drugs primarily suppress appetite, whereas FGF21 appears to increase metabolic rate.
Are any of these available as treatments?
No. Both are preclinical, and no approved drug targets these specific pathways.
What are the main limitations?
Both studies were in animals. The FGF21 work used only male mice, and the astrocyte team has not yet shown that manipulating HCAR1 alters feeding behavior.
Does this mean obesity is not about diet?
It means body weight is regulated by an extensive biological network. That does not make behavior irrelevant, but it helps explain why the system pushes back against change.
